IMV Aktie [WKN DE: A2JLZ3 / ISIN: CA44974L1031]

Kurse + Charts + Realtime		News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (groß)	News + Adhoc	Bilanz/GuV	Termine	Zertifikate	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil	Optionsscheine	Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV	Knock-Outs
Analysen

Kurse + Charts + Realtime
Kurs + Chart
Times + Sales
Börsenplätze

News + Analysen
News + Adhoc
Analysen
Kursziele

Fundamental
Bilanz/GuV
Schätzungen
Dividende/GV
Analysen

Unternehmen
Termine
Profil

zugeh. Wertpapiere
Zertifikate
Optionsscheine
Knock-Outs

Nachrichten zu IMV Inc Registered Shs

19.03.20		FDA Says No To Epilepsy Drug, IMV Advances COVID-19 Vaccine, ISEE Delays Study (RTTNews)
18.03.20		Stock Alert: IMV Up 32%; Plans To Develop Vaccine Against Covid-19 (RTTNews)
18.03.20		IMV Inc. Establishes At-the-Market Facility (Businesswire)
18.03.20		IMV Inc. Launches Plans to Advance Clinical Development of a Vaccine Candidate Against COVID-19 (Businesswire)
26.02.20		IOVA Abuzz, SUPN Study Flops, IMV Plunges Despite Positive Ovarian Cancer Data (RTTNews)
25.02.20		IMV Inc. Announces Breakthrough Data from DeCidE1, its Ongoing Phase 2 Study of DPX-Survivac in Patients with Advanced Recurrent Ovarian Cancer (Businesswire)
21.02.20		Stock Alert: What Will Decide IMV Stock Move? (RTTNews)
20.02.20		IMV to Host Conference Call & Webcast to Report Updated Results from DeCidE1, its Ongoing Phase 2 Study of DPX-Survivac in Patients with Advanced Recurrent Ovarian Cancer (Businesswire)
14.02.20		IMV Announces Board Retirement (Businesswire)
04.02.20		Clinical Translational Data Supporting DPX-Survivac Mechanism of Action to be Presented at 2020 ASCO-SITC Clinical Immuno-Oncology Symposium (Businesswire)
31.01.20		IMV to Present at 2020 BIO CEO & Investor Conference (Businesswire)
24.01.20		IMV to Host Key Opinion Leader Symposium on Role of Survivin in Cancer Biology and Potential of DPX-Survivac (Businesswire)
08.12.19		Updated Clinical Data from Phase 2 SPiReL Study Evaluating DPX-Survivac as a Combination Therapy in r/r DLBCL Presented at 61st American Society of Hematology (ASH) Annual Meeting (Businesswire)
27.11.19		IMV to Participate at Two Upcoming Investor Conferences (Businesswire)
08.11.19		IMV Inc. Announces Third Quarter 2019 Financial Results and Provides Corporate Update (Businesswire)
06.11.19		Updated Results from Phase 2 SPiReL Study Evaluating IMV’s DPX-Survivac as Combination Therapy in Patients with r/r DLBCL to be Presented at 61st American Society of Hematology (ASH) Annual Meeting (Businesswire)
05.11.19		IMV to Present Clinical Translational Data from DeCidE1 Study of DPX-Survivac at SITC 2019 Annual Meeting (Businesswire)
30.10.19		IMV Appoints Joanne Schindler, M.D., D.V.M. as Chief Medical Officer (Businesswire)
29.10.19		IMV Inc. to Announce Third Quarter 2019 Results and Host a Conference Call and Webcast on November 8, 2019 (Businesswire)
16.10.19		/ C O R R E C T I O N From Source – IMV Inc / (Businesswire)
11.10.19		IMV Inc. to Present at Upcoming Investor Conference (Businesswire)
30.09.19		Preliminary Results From IMV’s Phase 2 Basket Trial Evaluating DPX-Survivac as a Combination Therapy in Patients With Advanced and Metastatic Solid Tumors to Be Presented at ESMO Congress 2019 (Businesswire)
23.09.19		Preliminary Results From IMV’s Phase 2 Basket Trial Evaluating DPX-Survivac as a Combination Therapy in Patients with Advanced and Metastatic Solid Tumors to Be Presented at ESMO Congress 2019 (Businesswire)
04.09.19		IMV Announces Research Collaboration with The Wistar Institute to Develop New Targeted Immunotherapy Against the Common BRAF Cancer Mutation (Businesswire)
22.08.19		IMV Inc. to Present at Upcoming Investor Conferences (Businesswire)
08.08.19		IMV Inc. Announces Second Quarter 2019 Financial Results and Provides Company Update (Businesswire)
26.07.19		IMV Inc. to Present at the Canaccord Genuity 39th Annual Growth Conference (Businesswire)
25.07.19		IMV Inc. to Announce Second Quarter 2019 Results and Host a Conference Call and Webcast on August 9, 2019 (Businesswire)
13.06.19		IMV Inc. to Present at Two Upcoming Investor Conferences (Businesswire)
12.06.19		New Phase 2 Clinical Trial Results Continue to Demonstrate Potential Clinical Benefit of IMV’s DPX-Survivac in Combination with Merck’s Keytruda in Patients with DLBCL (Businesswire)
04.06.19		IMV Inc. to Provide Update on Phase 2 Clinical Results with Merck Keytruda in DLBCL by Means of Conference Call and Webcast on June 12, 2019 (Businesswire)
01.06.19		IMV Inc. Presents New Positive Data from Phase 2 Monotherapy Arm of Its Decide1 Trial in Advanced Ovarian Cancer and Continued Duration of Clinical Benefits to Patients with Progression Free Survival (Businesswire)
16.05.19		IMV to Present New Data at 2019 ASCO Annual Meeting From Its Phase 2 Clinical Trial Evaluating DPX-Survivac in Ovarian Cancer (Businesswire)
14.05.19		IMV Inc. to Present at Upcoming Investor Conferences (Businesswire)
10.05.19		IMV Announces Annual and Special Meeting of Shareholders Voting Results (Businesswire)
08.05.19		IMV Joins World Ovarian Cancer Coalition and Ovarian Cancer Canada in Supporting Ovarian Cancer Day 2019 (Businesswire)
26.04.19		IMV Inc. to Announce First Quarter 2019 Results and Host a Conference Call and Webcast on May 10, 2019 (Businesswire)
18.04.19		IMV to Provide Updated Clinical Data at 2019 ASCO Annual Meeting on Lead Candidate DPX-Survivac in Ovarian Cancer and Other Solid Tumors (Businesswire)
16.04.19		IMV Inc. Issues Statement on Recent Market Activity And Provides Corporate Update (Businesswire)
04.04.19		IMV Inc. to Present at the Bloom Burton & Co. Healthcare Investor Conference; Announces Update to Presentation at H.C. Wainwright Investor Conference (Businesswire)
03.04.19		New Preclinical Research Presented at AACR 2019 Reveals Unique Anti-Cancer Mechanism of Action Underscoring IMV’s Immunotherapy Program (Businesswire)
26.03.19		Initial Phase 2 Data From an IMV Clinical Study Continues to Demonstrate DPX-Survivac’s Prior Trend as a Potential Monotherapy Treatment for Advanced Ovarian Cancer (Businesswire)
25.03.19		IMV Inc. to Present at Two Upcoming Investor Conferences (Businesswire)
21.03.19		IMV Inc. Announces 2018 Year-end Financial and Operational Results and Provides Updates on Key Clinical Programs (Businesswire)
18.03.19		IMV and Centre de Recherche du CHU de Québec-Université Laval Collaboration Awarded a CQDM Grant to Develop First-in-Class Dual Target T Cell Therapy in Bladder Cancer Based on IMV’s DPX Technology (Businesswire)
12.03.19		IMV Researchers to Present New Preclinical Data at AACR Annual Meeting 2019 (Businesswire)
11.03.19		IMV Inc. Announces Partial Exercise of Option To Purchase Additional Shares in Connection with Underwritten Public Offering of Common Shares (Businesswire)
08.03.19		IMV Inc. to Announce 2018 Fourth Quarter and Fiscal Year-End Results and Host Investor Conference Call and Webcast on March 22, 2019 (Businesswire)
07.03.19		IMV Inc. to Present at the Cowen and Company 39th Annual Health Care Conference (Businesswire)
06.03.19		IMV Inc. Closes Previously Announced Public Offering (Businesswire)

Zurück | 1 | 2 | 3 | Weiter

Newssuche

Meistgelesene Nachrichten

Pierer Mobility-Aktie unter Druck: KTM-Pleite - Schockstarre in der Region und bei den Zulieferern - Land OÖ signalisiert Bereitschaft Beschäftigten zu helfen

voestalpine-Aktie zieht an: Erste Group stuft Aktie von "Accumulate" auf "Buy" hoch

Solana Kurs Prognose: 300 US-Dollar noch in diesem Jahr?

Rosenbauer erwartet kein Problem bei Kapitalerhöhung wegen KTM-Pleite - Rosenbauer-Aktie fester

Pierer Mobility-Aktie bricht ein: KTM steht vor Insolvenz

Pierer Mobility-Aktie zieht zweistellig an: Pierer Industrie AG hat Restrukturierungsverfahren eingeleitet

finanzen.net Apps

ETF-Sparplan

Oskar ist der einfache und intelligente ETF-Sparplan. Er übernimmt die ETF-Auswahl, ist steuersmart, transparent und kostengünstig.

JETZT MEHR ERFAHREN

Aktien ATX DAX EuroStoxx 50 Dow Jones NASDAQ 100 Nikkei 225 S&P 500

Kontakt - Impressum - Werbung

Sitemap - Datenschutz - Disclaimer - AGB - Privatsphäre-Einstellungen

Für die aufgeführten Inhalte kann keine Gewährleistung für die Vollständigkeit, Richtigkeit und Genauigkeit übernommen werden.
Kursinformationen von SIX Financial Information Deutschland GmbH. Verzögerung 15 Min. (Nasdaq, NYSE: 20 Min.).
© 1999-2024 finanzen.net GmbH

*Werbehinweise: Die Billigung des Basisprospekts durch die Bundesanstalt für Finanzdienstleistungsaufsicht ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.

⁵Hinweis zu Plus500: 82% der Kleinanlegerkonten verlieren Geld beim CFD-Handel mit diesem Anbieter. Sie sollten überlegen, ob Sie es sich leisten können, das hohe Risiko einzugehen, Ihr Geld zu verlieren. Plus500UK Ltd ist zugelassen und reguliert durch Financial Conduct Authority (FRN 509909). Plus500CY Ltd authorized & regulated by CySEC (#250/14).

Währungsrechner News Devisen Dollarkurs Aktienkurse Bitcoin Rohstoffe Fonds

Portfolioname: Watchlistname:
Portfolio:
Name:
Typ:
ISIN:
Börse:
Anzahl:
Aktueller Kurs:
Kurszeit:
Kaufpreis:
Kaufdatum:	30.11.2024 05:58
Kaufwert:	EUR
	Hinzufügen Speichern